RT Journal Article SR Electronic T1 Cancer Imaging with Radiolabeled Antibodies: New Advances with Technetium-99m-Labeled Monoclonal Antibody Fab’ Fragments, Especially CEA-Scan® and Prospects for Therapy JF Journal of Nuclear Medicine Technology JO J. Nucl. Med. Technol. FD Society of Nuclear Medicine SP 18 OP 23 VO 25 IS 1 A1 David M. Goldenberg A1 Malik Juweid A1 Robert M. Dunn A1 Robert M. Sharkey YR 1997 UL http://tech.snmjournals.org/content/25/1/18.abstract AB The use of radiolabeled anticancer antibodies to detect cancer sites by external scintigraphy has had a relatively long history. With the advent of monoclonal antibodies (MAbs), which precluded the need for purifying the antibodies by laborious purification steps, there was a surge of interest and efforts to develop these reagents for both imaging and therapy applications (1). Today, many thousands of patients have received different forms and doses of MAbs for various purposes, and four MAb-based products have been licensed for manufacture and sale in the U.S. (2,3). This article describes the most recent MAb product to be approved in the U.S. for colorectal cancer imaging, including discussions of using this agent and its therapeutic counterpart in several cancer types.